Cell therapy company AvenCell raises up to $47 million from Ligand
AvenCell Therapeutics Issuer · Ligand Pharmaceuticals Investor
Intelligence
The deal
- Type
- Funding
- Amount
- up to $47M
- Structure
- Up to $41 million for a royalty on AvenCell pipeline sales, in four tranches, plus up to $6 million of Series C
- Status
- Announced
- Round
- Royalty financing plus Series C
- Valuation
- Not recorded
- Region
- United States
- Date
- 24 September 2026
As of this development: a later development may record new terms.
Lifecycle
- Announced
- Closed
The parties
AvenCell Therapeutics Issuer
Ligand Pharmaceuticals Investor
Activity